Washington, DC: Clinical reviews published in the current issues of the journals Nature Reviews Immunology and Trends in Neurosciences tout the ability of cannabinoids and cannabis-derived medications to treat multiple sclerosis, cancer and numerous other medical conditions.
The first clinical review, published by researchers at London’s University College, Institute of Neurology, notes that “abundant experimental data … combined with data from recent trials points to the prospect of cannabis as a medication in the treatment of multiple sclerosis and numerous other medical conditions.”
The second clinical review, published by a researcher at the University of South Florida College of Medicine and appearing in the prestigious journal Nature Reviews Immunology, notes that cannabinoids have proven immunosuppressive and anti-inflammatory properties and may be useful in the treatment of “chronic inflammatory diseases,” as well as various other conditions, including cancer and spasticity.
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Full text of the review, “Emerging properties of cannabinoid medicines in management of multiple sclerosis,” appears in the May issue of Trends in Neuroscience. Full text of the review, “Cannabinoid-based drugs as anti-inflammatory therapeutics,” appears in the May issue of Nature Reviews Immunology.